vs
Protalix BioTherapeutics, Inc.（PLX）与UNITED SECURITY BANCSHARES（UBFO）财务数据对比。点击上方公司名可切换其他公司
UNITED SECURITY BANCSHARES的季度营收约是Protalix BioTherapeutics, Inc.的1.5倍（$13.5M vs $9.1M），UNITED SECURITY BANCSHARES净利率更高（25.2% vs -60.3%，领先85.5%），UNITED SECURITY BANCSHARES同比增速更快（13.6% vs -49.9%），UNITED SECURITY BANCSHARES自由现金流更多（$19.8M vs $1.6M），过去两年UNITED SECURITY BANCSHARES的营收复合增速更高（3.0% vs -6.7%）
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
联合安全银行控股公司（United Security Bancshares）是一家银行控股公司，总部位于加利福尼亚州弗雷斯诺，目前在当地共运营11家线下分支网点。
PLX vs UBFO — 直观对比
营收规模更大
UBFO
是对方的1.5倍
$9.1M
营收增速更快
UBFO
高出63.5%
-49.9%
净利率更高
UBFO
高出85.5%
-60.3%
自由现金流更多
UBFO
多$18.1M
$1.6M
两年增速更快
UBFO
近两年复合增速
-6.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $9.1M | $13.5M |
| 净利润 | $-5.5M | $3.4M |
| 毛利率 | 49.4% | — |
| 营业利润率 | -51.1% | 31.5% |
| 净利率 | -60.3% | 25.2% |
| 营收同比 | -49.9% | 13.6% |
| 净利润同比 | -184.8% | 36.8% |
| 每股收益（稀释后） | $-0.06 | $0.18 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PLXUBFO
| Q4 25 | $9.1M | $13.5M | ||
| Q3 25 | $17.9M | $14.0M | ||
| Q2 25 | $15.7M | $12.6M | ||
| Q1 25 | $10.1M | $13.7M | ||
| Q4 24 | $18.2M | $11.9M | ||
| Q3 24 | $18.0M | $13.8M | ||
| Q2 24 | $13.5M | $13.0M | ||
| Q1 24 | — | $12.8M |
净利润PLXUBFO
| Q4 25 | $-5.5M | $3.4M | ||
| Q3 25 | $2.4M | $4.0M | ||
| Q2 25 | $164.0K | $2.2M | ||
| Q1 25 | $-3.6M | $2.7M | ||
| Q4 24 | $6.5M | $2.5M | ||
| Q3 24 | $3.2M | $3.8M | ||
| Q2 24 | $-2.2M | $4.3M | ||
| Q1 24 | — | $4.2M |
毛利率PLXUBFO
| Q4 25 | 49.4% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 62.5% | — | ||
| Q1 25 | 19.1% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 53.4% | — | ||
| Q2 24 | 29.8% | — | ||
| Q1 24 | — | — |
营业利润率PLXUBFO
| Q4 25 | -51.1% | 31.5% | ||
| Q3 25 | 11.9% | 40.3% | ||
| Q2 25 | 7.5% | 24.0% | ||
| Q1 25 | -41.0% | 27.5% | ||
| Q4 24 | 39.6% | 27.5% | ||
| Q3 24 | 22.2% | 37.1% | ||
| Q2 24 | -18.0% | 46.4% | ||
| Q1 24 | — | 45.9% |
净利率PLXUBFO
| Q4 25 | -60.3% | 25.2% | ||
| Q3 25 | 13.2% | 28.7% | ||
| Q2 25 | 1.0% | 17.2% | ||
| Q1 25 | -35.8% | 19.6% | ||
| Q4 24 | 35.6% | 20.9% | ||
| Q3 24 | 18.0% | 27.7% | ||
| Q2 24 | -16.4% | 33.0% | ||
| Q1 24 | — | 32.6% |
每股收益（稀释后）PLXUBFO
| Q4 25 | $-0.06 | $0.18 | ||
| Q3 25 | $0.03 | $0.23 | ||
| Q2 25 | $0.00 | $0.13 | ||
| Q1 25 | $-0.05 | $0.16 | ||
| Q4 24 | $0.10 | $0.14 | ||
| Q3 24 | $0.03 | $0.22 | ||
| Q2 24 | $-0.03 | $0.25 | ||
| Q1 24 | — | $0.24 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $14.7M | $264.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $48.2M | $139.7M |
| 总资产 | $82.3M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PLXUBFO
| Q4 25 | $14.7M | $264.2M | ||
| Q3 25 | $13.6M | $211.1M | ||
| Q2 25 | $17.9M | $199.5M | ||
| Q1 25 | $19.5M | $198.4M | ||
| Q4 24 | $19.8M | $216.9M | ||
| Q3 24 | $27.4M | $216.8M | ||
| Q2 24 | $23.4M | $166.3M | ||
| Q1 24 | — | $168.6M |
股东权益PLXUBFO
| Q4 25 | $48.2M | $139.7M | ||
| Q3 25 | $52.9M | $137.4M | ||
| Q2 25 | $49.9M | $134.3M | ||
| Q1 25 | $45.2M | $132.9M | ||
| Q4 24 | $43.2M | $130.4M | ||
| Q3 24 | $32.4M | $132.9M | ||
| Q2 24 | $28.6M | $127.3M | ||
| Q1 24 | — | $124.2M |
总资产PLXUBFO
| Q4 25 | $82.3M | $1.2B | ||
| Q3 25 | $82.3M | $1.2B | ||
| Q2 25 | $78.5M | $1.2B | ||
| Q1 25 | $73.9M | $1.2B | ||
| Q4 24 | $73.4M | $1.2B | ||
| Q3 24 | $61.6M | $1.3B | ||
| Q2 24 | $91.5M | $1.2B | ||
| Q1 24 | — | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.0M | $22.1M |
| 自由现金流经营现金流 - 资本支出 | $1.6M | $19.8M |
| 自由现金流率自由现金流/营收 | 17.8% | 146.0% |
| 资本支出强度资本支出/营收 | 4.4% | 16.8% |
| 现金转化率经营现金流/净利润 | — | 6.46× |
| 过去12个月自由现金流最近4个季度 | $-13.6M | $36.9M |
8季度趋势，按日历期对齐
经营现金流PLXUBFO
| Q4 25 | $2.0M | $22.1M | ||
| Q3 25 | $-3.7M | $7.0M | ||
| Q2 25 | $-5.2M | $8.7M | ||
| Q1 25 | $-5.1M | $3.0M | ||
| Q4 24 | $4.0M | $19.6M | ||
| Q3 24 | $4.1M | $5.4M | ||
| Q2 24 | $-3.6M | $2.3M | ||
| Q1 24 | — | $7.4M |
自由现金流PLXUBFO
| Q4 25 | $1.6M | $19.8M | ||
| Q3 25 | $-4.2M | $6.1M | ||
| Q2 25 | $-5.7M | $8.1M | ||
| Q1 25 | $-5.4M | $2.9M | ||
| Q4 24 | $3.6M | $18.6M | ||
| Q3 24 | $4.0M | $5.3M | ||
| Q2 24 | $-3.8M | $2.0M | ||
| Q1 24 | — | $7.0M |
自由现金流率PLXUBFO
| Q4 25 | 17.8% | 146.0% | ||
| Q3 25 | -23.7% | 43.7% | ||
| Q2 25 | -36.2% | 64.3% | ||
| Q1 25 | -53.0% | 21.2% | ||
| Q4 24 | 19.6% | 156.0% | ||
| Q3 24 | 22.4% | 38.1% | ||
| Q2 24 | -28.1% | 15.5% | ||
| Q1 24 | — | 54.8% |
资本支出强度PLXUBFO
| Q4 25 | 4.4% | 16.8% | ||
| Q3 25 | 2.8% | 6.0% | ||
| Q2 25 | 2.8% | 4.6% | ||
| Q1 25 | 3.0% | 0.9% | ||
| Q4 24 | 2.3% | 8.7% | ||
| Q3 24 | 0.5% | 0.7% | ||
| Q2 24 | 1.3% | 2.2% | ||
| Q1 24 | — | 3.6% |
现金转化率PLXUBFO
| Q4 25 | — | 6.46× | ||
| Q3 25 | -1.58× | 1.73× | ||
| Q2 25 | -31.91× | 4.01× | ||
| Q1 25 | — | 1.13× | ||
| Q4 24 | 0.61× | 7.87× | ||
| Q3 24 | 1.27× | 1.40× | ||
| Q2 24 | — | 0.54× | ||
| Q1 24 | — | 1.79× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
UBFO
暂无分部数据
